Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer
Articolo
Data di Pubblicazione:
2001
Citazione:
Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line
Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer / G. Bolis, G. Scarfone, G. Giardina, A. Villa, G. Mangili, M. Melpignano, M. Presti, S. Tateo, M. Franchi, F. Parazzini. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - 81:1(2001 Apr), pp. 3-9. [10.1006/gyno.2001.6151]
Abstract:
Objective. The aim of the study was to analyze the benefit/
toxicity profile of a second-line treatment with carboplatin alone
or carboplatin plus another non-cross-resistant drug (epidoxorubicin)
in ovarian cancer patients sensitive to cisplatin-based chemotherapy
at first-line treatment.
Methods. We conducted a randomized clinical trial. Women
with epithelial ovarian cancer FIGO Stage II–IV who had a
complete or partial response to first-line treatment with cisplatin
or carboplatin-based regiments and subsequently progressed or
relapsed more than 6 months after discontinuation of first-line
treatment were eligible for the study. A total of 190 subjects
entered the study. They were randomly allocated to either 300
mg/m2 of carboplatin every 28 days for five cycles (95 patients) or
120 mg/m2 of epidoxorubicin and 300 mg/m2 of carboplatin every
28 days for five cycles (95 patients).
Results. A complete response was reported, respectively, in 32
(36%) women allocated to carboplatin alone and in 28 (31.8%) of
those allocated to carboplatin plus epidoxorubicin. The corresponding
figures for partial response were 18 (20.2%) and 26
(29.9%). Comparing the frequency of complete response, partial
response, no change, and progression, the differences between the
two groups were not significant (x3
2 5.10, P 5 0.16). The median
duration of response was 16 months in the carboplatin alone and
20 months in the carboplatin plus epidoxorubicin group (P 5 not
significant). The 3-year percentage of survival was 29% in the
carboplatin alone and 42% in the carboplatin plus epidoxorubicin
group; this difference was not statistically significant. The frequency
of leukopenia, anemia, and thrombocytopenia grade 3–4
was higher in the epidoxorubicin plus carboplatin than in the
carboplatin alone group. Alopecia G3 was present in 88% of
women treated with epidoxorubicin plus carboplatin.
Conclusions. The general results of this study do not show any
marked differences in response to second-line treatment among
women treated with single-agent (carboplatin) or multiagent (carboplatin
plus epidoxorubicin) schedules. Toxicity, particularly hematological,
was more relevant in women treated with the multiagent
schedule.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
ovarian cancer ; chemotherapy ; recurrence
Elenco autori:
G. Bolis, G. Scarfone, G. Giardina, A. Villa, G. Mangili, M. Melpignano, M. Presti, S. Tateo, M. Franchi, F. Parazzini
Link alla scheda completa: